Alberto Goday1,2,3,4, Olga Castañer5,6,7, David Benaiges1,2,3, Anna Busquets Pou3, José M Ramón8, Maria Del Mar Iglesias3,9, Luis Barranco Priego10, Juana A Flores Le-Roux1,3. 1. Department of Endocrinology and Nutrition, Hospital del Mar Research Institute, Passeig Marítim 25-29, 08003, Barcelona, Spain. 2. Cardiovascular Risk and Nutrition Research Group (CARIN-ULEC), IMIM-Hospital del Mar Research Institute, Biomedical Research Park (Parc de Recerca Biomèdica de Barcelona - PRBB), Barcelona, Spain. 3. Department of Medicine, University Autònoma de Barcelona-Universitat Pompeu Fabra, Barcelona, Spain. 4. Centro de Investigaciones Biomédicas en Red de Obesidad y Nutrición, CIBERobn, Barcelona, Spain. 5. Department of Endocrinology and Nutrition, Hospital del Mar Research Institute, Passeig Marítim 25-29, 08003, Barcelona, Spain. ocastaner@imim.es. 6. Cardiovascular Risk and Nutrition Research Group (CARIN-ULEC), IMIM-Hospital del Mar Research Institute, Biomedical Research Park (Parc de Recerca Biomèdica de Barcelona - PRBB), Barcelona, Spain. ocastaner@imim.es. 7. Centro de Investigaciones Biomédicas en Red de Obesidad y Nutrición, CIBERobn, Barcelona, Spain. ocastaner@imim.es. 8. Unit of Gastrointestinal Surgery, Hospital del Mar, Hospital del Mar Research Institute, Barcelona, Spain. 9. Pathology Unit, Hospital del Mar, Hospital del Mar Research Institute, Barcelona, Spain. 10. Department of Gastroenterology, Hospital del Mar Research Institute, Barcelona, Spain.
Abstract
BACKGROUND: Helicobacter pylori (HP) colonization is common in severely obese patients undergoing bariatric surgery. HP eradication treatment could influence the evolution of weight loss and metabolic markers after bariatric surgery. OBJECTIVE: To assess the influence of HP eradication in the clinical course of morbid obesity patients treated with bariatric surgery (gastric bypass (LRYGB) and sleeve gastrectomy (LSG)) METHODS: Retrospective analysis of a prospective cohort of 229 patients that underwent bariatric surgery between 2010 and 2013 in Hospital del Mar. HP infection was tested preoperatively by gastric biopsy and, if positive, treated with omeprazole, clarithromycin, and amoxicillin for 14 days. Patients were followed at 3, 6, 12, 18, and 24 months after bariatric surgery. Short-term weight loss and metabolic outcomes were evaluated. RESULTS: HP treated (HPt) patients had a greater reduction in BMI at 3 months after LSG (ΔBMI (kg/cm2) 8.5 ± 4.1 vs 11.3 ± 3.05 kg/m2; p = 0.004) and a reduction in the evolution of triglyceride levels from baseline to 12 months (p = 0.014) compared to HP-negative (HP-) subjects. Also, non-diabetic HPt patients had a greater reduction in glucose levels at all time points that was maintained up to 24 months after LRYGB (p = 0.003). No differences were observed in total and LDL cholesterol levels, HOMA-IR, or HbA1C. CONCLUSIONS: Preoperative HP eradication has a short-term influence on some metabolic parameters after bariatric surgery.
BACKGROUND:Helicobacter pylori (HP) colonization is common in severely obesepatients undergoing bariatric surgery. HP eradication treatment could influence the evolution of weight loss and metabolic markers after bariatric surgery. OBJECTIVE: To assess the influence of HP eradication in the clinical course of morbid obesitypatients treated with bariatric surgery (gastric bypass (LRYGB) and sleeve gastrectomy (LSG)) METHODS: Retrospective analysis of a prospective cohort of 229 patients that underwent bariatric surgery between 2010 and 2013 in Hospital del Mar. HP infection was tested preoperatively by gastric biopsy and, if positive, treated with omeprazole, clarithromycin, and amoxicillin for 14 days. Patients were followed at 3, 6, 12, 18, and 24 months after bariatric surgery. Short-term weight loss and metabolic outcomes were evaluated. RESULTS:HP treated (HPt) patients had a greater reduction in BMI at 3 months after LSG (ΔBMI (kg/cm2) 8.5 ± 4.1 vs 11.3 ± 3.05 kg/m2; p = 0.004) and a reduction in the evolution of triglyceride levels from baseline to 12 months (p = 0.014) compared to HP-negative (HP-) subjects. Also, non-diabetic HPtpatients had a greater reduction in glucose levels at all time points that was maintained up to 24 months after LRYGB (p = 0.003). No differences were observed in total and LDL cholesterol levels, HOMA-IR, or HbA1C. CONCLUSIONS: Preoperative HP eradication has a short-term influence on some metabolic parameters after bariatric surgery.
Entities:
Keywords:
Bariatric surgery; Gut microbiota; Helicobacter pylori; Morbid obesity
Authors: Anne Vrieze; Els Van Nood; Frits Holleman; Jarkko Salojärvi; Ruud S Kootte; Joep F W M Bartelsman; Geesje M Dallinga-Thie; Mariette T Ackermans; Mireille J Serlie; Raish Oozeer; Muriel Derrien; Anne Druesne; Johan E T Van Hylckama Vlieg; Vincent W Bloks; Albert K Groen; Hans G H J Heilig; Erwin G Zoetendal; Erik S Stroes; Willem M de Vos; Joost B L Hoekstra; Max Nieuwdorp Journal: Gastroenterology Date: 2012-06-20 Impact factor: 22.682
Authors: S Sauerland; L Angrisani; M Belachew; J M Chevallier; F Favretti; N Finer; A Fingerhut; M Garcia Caballero; J A Guisado Macias; R Mittermair; M Morino; S Msika; F Rubino; R Tacchino; R Weiner; E A M Neugebauer Journal: Surg Endosc Date: 2004-12-02 Impact factor: 4.584
Authors: J P Gisbert; D Boixeda; C Redondo; I Alvarez Baleriola; I Jiménez; J I Pérez García; J M Pajares Journal: Rev Esp Enferm Dig Date: 1996-04 Impact factor: 2.086
Authors: M A Küper; T Kratt; K M Kramer; M Zdichavsky; J H Schneider; J Glatzle; D Stüker; A Königsrainer; B L D M Brücher Journal: Surg Endosc Date: 2010-02-05 Impact factor: 4.584
Authors: J Picot; J Jones; J L Colquitt; E Gospodarevskaya; E Loveman; L Baxter; A J Clegg Journal: Health Technol Assess Date: 2009-09 Impact factor: 4.014